Mercury Laboratories Ltd

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 1 July 2026. This change is primarily driven by a significant improvement in valuation metrics, even as the company’s financial performance remains flat and its long-term fundamentals continue to show weakness.

Mercury Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite a challenging sector environment. This micro-cap pharmaceutical player now presents a compelling price proposition relative to its historical averages and peer group, signalling a potential inflection point for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 June 2026, providing investors with the latest view of the company’s position.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s quarterly operating profit and margins have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 May 2026. This shift reflects deteriorating technical indicators, subdued financial trends, and a cautious outlook on quality metrics despite an attractive valuation profile. The downgrade underscores growing concerns over the company’s long-term fundamentals and market performance relative to peers and benchmarks.

Mercury Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as its share price surged nearly 20% in a single day. Despite this rally, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with industry peers, signalling a recalibration of price attractiveness in the Pharmaceuticals & Biotechnology sector.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 22 May 2026. This change reflects a nuanced shift in the company’s technical outlook amid ongoing challenges in its fundamental and valuation metrics. While the technical indicators have improved modestly, the company continues to face headwinds in long-term financial trends and relative market performance.

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with an up-to-date view of the company’s standing.

Mercury Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 May 2026, reflecting deteriorating technical indicators and persistent fundamental challenges. Despite some positive quarterly financial results, the company’s overall outlook has weakened due to bearish technical trends, subdued long-term financial growth, and valuation concerns within the pharmaceuticals sector.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook amid mixed financial and valuation metrics. While the company’s recent quarterly performance shows promise, long-term fundamentals and market returns continue to weigh on investor sentiment.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 Mar 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 02 May 2026, providing investors with the latest insights into its performance and outlook.

A sharp decline of 19.41% intraday has dragged Mercury Laboratories Ltd to a fresh 52-week low of Rs 620.55 on 24 Apr 2026, marking a significant setback for the micro-cap pharmaceutical player amid a broadly weak market environment.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 March 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s performance and outlook.